Literature DB >> 21452260

2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features.

Timothy Beukelman1, Nivedita M Patkar, Kenneth G Saag, Sue Tolleson-Rinehart, Randy Q Cron, Esi Morgan DeWitt, Norman T Ilowite, Yukiko Kimura, Ronald M Laxer, Daniel J Lovell, Alberto Martini, C Egla Rabinovich, Nicolino Ruperto.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21452260      PMCID： PMC3222233          DOI： 10.1002/acr.20460

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN： 2151-464X            Impact factor:   4.794


× No keyword cloud information.
  106 in total

Review 1.  American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis.

Authors:  Jennifer M Grossman; Rebecca Gordon; Veena K Ranganath; Chad Deal; Liron Caplan; Weiling Chen; Jeffrey R Curtis; Daniel E Furst; Maureen McMahon; Nivedita M Patkar; Elizabeth Volkmann; Kenneth G Saag
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-07-26       Impact factor: 4.794

2.  Prevention of leg length discrepancy in young children with pauciarticular juvenile rheumatoid arthritis by treatment with intraarticular steroids.

Authors:  D D Sherry; L D Stein; A M Reed; L E Schanberg; D W Kredich
Journal:  Arthritis Rheum       Date:  1999-11

3.  Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group.

Authors:  D J Lovell; E H Giannini; A Reiff; G D Cawkwell; E D Silverman; J J Nocton; L D Stein; A Gedalia; N T Ilowite; C A Wallace; J Whitmore; B K Finck
Journal:  N Engl J Med       Date:  2000-03-16       Impact factor: 91.245

4.  Juvenile chronic arthritis into adulthood: a long-term follow-up study.

Authors:  M Zak; F K Pedersen
Journal:  Rheumatology (Oxford)       Date:  2000-02       Impact factor: 7.580

Review 5.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.

Authors:  Josef S Smolen; Robert Landewé; Ferdinand C Breedveld; Maxime Dougados; Paul Emery; Cecile Gaujoux-Viala; Simone Gorter; Rachel Knevel; Jackie Nam; Monika Schoels; Daniel Aletaha; Maya Buch; Laure Gossec; Tom Huizinga; Johannes W J W Bijlsma; Gerd Burmester; Bernard Combe; Maurizio Cutolo; Cem Gabay; Juan Gomez-Reino; Marios Kouloumas; Tore K Kvien; Emilio Martin-Mola; Iain McInnes; Karel Pavelka; Piet van Riel; Marieke Scholte; David L Scott; Tuulikki Sokka; Guido Valesini; Ronald van Vollenhoven; Kevin L Winthrop; John Wong; Angela Zink; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2010-05-05       Impact factor: 19.103

6.  Development and validation of a composite disease activity score for juvenile idiopathic arthritis.

Authors:  Alessandro Consolaro; Nicolino Ruperto; Anna Bazso; Angela Pistorio; Silvia Magni-Manzoni; Giovanni Filocamo; Clara Malattia; Stefania Viola; Alberto Martini; Angelo Ravelli
Journal:  Arthritis Rheum       Date:  2009-05-15

7.  Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register.

Authors:  F H M Prince; M Twilt; R ten Cate; M A J van Rossum; W Armbrust; E P A H Hoppenreijs; M van Santen-Hoeufft; Y Koopman-Keemink; N M Wulffraat; L W A van Suijlekom-Smit
Journal:  Ann Rheum Dis       Date:  2008-04-15       Impact factor: 19.103

8.  Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents.

Authors:  Ricardo A G Russo; María M Katsicas
Journal:  J Rheumatol       Date:  2009-05       Impact factor: 4.666

9.  Anakinra for systemic juvenile arthritis: the Rocky Mountain experience.

Authors:  Andrew Zeft; Roger Hollister; Bonnie LaFleur; Prahalad Sampath; Jennifer Soep; Bernadette McNally; Gary Kunkel; Margaret Schlesinger; John Bohnsack
Journal:  J Clin Rheumatol       Date:  2009-06       Impact factor: 3.517

10.  Monitoring methotrexate toxicity in juvenile idiopathic arthritis.

Authors:  Lakshmi Kocharla; Janalee Taylor; Tracey Weiler; Tracy V Ting; Michael Luggen; Hermine I Brunner
Journal:  J Rheumatol       Date:  2009-11-16       Impact factor: 4.666
View more
  202 in total

Review 1.  Defining juvenile idiopathic arthritis remission and optimum time for disease-modifying anti-rheumatic drug withdrawal: why we need a consensus.

Authors:  Thomas Broughton; Kate Armon
Journal:  Paediatr Drugs       Date:  2012-02-01       Impact factor: 3.022

Review 2.  JIA in 2011: New takes on categorization and treatment.

Authors:  Alberto Martini
Journal:  Nat Rev Rheumatol       Date:  2012-01-10       Impact factor: 20.543

3.  Juvenile spondyloarthritis treatment recommendations.

Authors:  Shirley M L Tse; Ruben Burgos-Vargas; Robert A Colbert
Journal:  Am J Med Sci       Date:  2012-05       Impact factor: 2.378

Review 4.  Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials.

Authors:  Simon Tarp; Gil Amarilyo; Ivan Foeldvari; Robin Christensen; Jennifer M P Woo; Neta Cohen; Tracy D Pope; Daniel E Furst
Journal:  Rheumatology (Oxford)       Date:  2015-11-30       Impact factor: 7.580

5.  Expert's comment concerning Grand Rounds case entitled "The surgical management of atlanto-axial subluxation in juvenile rheumatoid arthritis" (Khalid M. I. Salem et al. Eur Spine J; 2014, DOI 10.1007/s00586-014-3648-5).

Authors:  Kishore Chandran Warrier
Journal:  Eur Spine J       Date:  2016-01-21       Impact factor: 3.134

Review 6.  Biologic-associated infections in pediatric rheumatology.

Authors:  Gerd Horneff
Journal:  Curr Rheumatol Rep       Date:  2015-11       Impact factor: 4.592

Review 7.  Glucocorticoid treatment in juvenile idiopathic arthritis.

Authors:  Ezgi Deniz Batu
Journal:  Rheumatol Int       Date:  2018-10-01       Impact factor: 2.631

8.  Bayesian comparative effectiveness study of four consensus treatment plans for initial management of systemic juvenile idiopathic arthritis: FiRst-Line Options for Systemic juvenile idiopathic arthritis Treatment (FROST).

Authors:  Peter A Nigrovic; Timothy Beukelman; George Tomlinson; Brian M Feldman; Laura E Schanberg; Yukiko Kimura
Journal:  Clin Trials       Date:  2018-03-15       Impact factor: 2.486

9.  2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications.

Authors:  Sarah Ringold; Pamela F Weiss; Timothy Beukelman; Esi Morgan DeWitt; Norman T Ilowite; Yukiko Kimura; Ronald M Laxer; Daniel J Lovell; Peter A Nigrovic; Angela Byun Robinson; Richard K Vehe
Journal:  Arthritis Rheum       Date:  2013-10

10.  Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis.

Authors:  Shumpei Yokota; Toshio Tanaka; Tadamitsu Kishimoto
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-12       Impact factor: 5.346
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.